[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiang Luo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":121},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,68,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100637603","phase-2-minocycline-after-successful-endovascular-thrombectomy-recanalization-in-acute-anterior-circulation-large-vessel-occlusion-attraction-minoa-100637603",false,"NCT07594314","Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)","Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Anterior Circulation Large Vessel Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Pre-stroke mRS score of 0-1;\n3. Time from symptom onset to randomization ≤24 hours, including wake-up stroke or unwitnessed stroke. Symptom onset is defined as the last known well time;\n4. Baseline NIHSS score of 6-25;\n5. ASPECTS ≥6 on non-contrast CT or DWI;\n6. Clinical symptoms attributable to acute occlusion at one of the following sites, confirmed by CTA, MRA, or DSA: intracranial internal carotid artery, M1 segment of the middle cerebral artery, or M2 trunk of the MCA;\n7. Successful recanalization defined as mTICI 2b-3 after mechanical thrombectomy, with no evidence of secondary embolization in non-target vessels; or spontaneous improvement to mTICI 2b-3 on diagnostic angiography prior to thrombectomy with no planned intervention;\n8. Ability of the patient or legally authorized representative to provide written informed consent.\n\nExclusion Criteria:\n\n1. Acute intracranial hemorrhage on CT or MRI;\n2. Bilateral acute stroke or multiple intracranial large vessel occlusions;\n3. Isolated extracranial internal carotid artery occlusion;\n4. History of pseudomembranous colitis or antibiotic-associated colitis;\n5. Known allergy to tetracycline antibiotics, any component of the investigational drug, radiocontrast agents, or nitinol materials;\n6. Known resistance to tetracycline antibiotics;\n7. Use of tetracycline antibiotics within 7 days prior to randomization;\n8. History of intracranial hemorrhage within the past 3 months, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma;\n9. Intracranial tumors, vascular malformations, or other space-occupying intracranial lesions;\n10. History of intracranial or spinal surgery within the past 3 months;\n11. History of major surgery or significant trauma within the past 1 month;\n12. Receipt of any of the following treatments within the past 3 months: systemic retinoic acid or androgen\u002Fantiandrogen therapy (e.g., anabolic steroids, spironolactone);\n13. Platelet count \\\u003C100 × 10⁹\u002FL;\n14. Severe hepatic insufficiency, chronic hemodialysis, or severe renal insufficiency (defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin or serum creatinine \\>265.2 μmol\u002FL \\[3.0 mg\u002FdL\\]);\n15. Women who are pregnant or lactating, or who have a positive pregnancy test prior to randomization;\n16. Life expectancy \\\u003C6 months (e.g., due to malignancy or severe cardiopulmonary disease);\n17. Participation in another interventional clinical trial that may affect outcome assessment;\n18. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation or poses significant risk (e.g., inability to understand or comply with study procedures or follow-up due to psychiatric, cognitive, or emotional disorders).","ALL","18 Years",{"count":19,"type":20},860,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","Endovascular thrombectomy (EVT) improves outcomes in patients with acute large vessel occlusion (LVO). However, despite successful recanalization rates exceeding 80%, fewer than 50% of patients achieve favorable functional outcomes at 90 days, indicating a high rate of futile recanalization. Potential mechanisms include no-reflow, reperfusion injury, and microcirculatory dysfunction, which are closely associated with post-recanalization neuroinflammation.\n\nMinocycline is a second-generation tetracycline with pleiotropic neuroprotective effects, including inhibition of microglial activation, reduction of inflammatory mediators, suppression of matrix metalloproteinases, attenuation of oxidative stress, and preservation of blood-brain barrier integrity. Prior preclinical and clinical studies suggest that minocycline may improve neurological outcomes in acute ischemic stroke.\n\nThis study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate the safety and efficacy of adjunctive minocycline in patients with acute anterior circulation LVO who achieve successful recanalization after EVT. The trial will assess whether early administration of minocycline improves functional outcomes and reduces futile recanalization.",[27,28,29,30,31],"Acute Ischemic Stroke","Vessel Occlusion","Endovascular Thrombectomy","Anterior Circulation Brain Infarction","Minocycline",[27,29,31,33],"Anterior Circulation Large Vessel Occlusion","RECRUITING","2026-05-22",{"date":37,"type":38},"2026-05-27","ACTUAL",{"date":40,"type":38},"2026-05-21",{"date":42,"type":20},"2028-12",{"name":44,"class":45},"Xiang Luo","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":66,"leadSponsor":67,"locationsCount":46},"100637132","phase-2-minocycline-after-successful-endovascular-thrombectomy-recanalization-in-posterior-circulation-arterial-occlusion-attraction-minop-100637132","NCT07594301","Minocycline After Successful Endovascular Thrombectomy Recanalization in Posterior Circulation Arterial Occlusion (ATTRACTION-MINOP)","Safety and Efficacy of Adjunctive Minocycline After Successful Endovascular Thrombectomy Recanalization for Acute Posterior Circulation Arterial Occlusion - A Multicenter, Prospective, Double-blind, Randomized Trial","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Pre-stroke mRS score of 0-1;\n3. Time from symptom onset to randomization ≤24 hours, including wake-up stroke or unwitnessed stroke. Symptom onset is defined as the last known well time;\n4. Baseline NIHSS score ≥6;;\n5. Posterior Circulation ASPECTS ≥6 on non-contrast CT or DWI;\n6. Clinical symptoms attributable to acute occlusion of the intracranial vertebral artery or basilar artery, confirmed by CTA, MRA, or DSA;\n7. Successful recanalization defined as mTICI 2b-3 after mechanical thrombectomy, with no evidence of secondary embolization in non-target vessels; or spontaneous improvement to mTICI 2b-3 on diagnostic angiography prior to thrombectomy with no planned intervention;\n8. Ability of the patient or legally authorized representative to provide written informed consent.\n\nExclusion Criteria:\n\n1. Acute intracranial hemorrhage on CT or MRI;\n2. Occlusion involving both anterior and posterior circulations on CTA, MRA, or DSA (except in patients with a prior history of anterior circulation occlusion);\n3. Complete bilateral thalamic infarction or bilateral brainstem infarction on CT or MRI;\n4. Cerebellar infarction with significant mass effect or compression of the fourth ventricle on CT or MRI;\n5. Vascular anatomy on CTA, MRA, or DSA that is severely tortuous, demonstrates significant anatomical variation, or shows severe stenosis or dissection precluding navigation of thrombectomy devices to the target vessel;\n6. History of pseudomembranous colitis or antibiotic-associated colitis;\n7. Known allergy to tetracycline antibiotics, any component of the investigational drug, radiocontrast agents, or nitinol materials;\n8. Known resistance to tetracycline antibiotics;\n9. Use of tetracycline antibiotics within 7 days prior to randomization;\n10. History of intracranial hemorrhage within the past 3 months, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma;\n11. Intracranial tumors, vascular malformations, or other space-occupying intracranial lesions;\n12. History of intracranial or spinal surgery within the past 3 months;\n13. History of major surgery or significant trauma within the past 1 month;\n14. Receipt of any of the following treatments within the past 3 months: systemic retinoic acid or androgen\u002Fantiandrogen therapy (e.g., anabolic steroids, spironolactone);\n15. Platelet count \\\u003C100 × 10⁹\u002FL;\n16. Severe hepatic insufficiency, chronic hemodialysis, or severe renal insufficiency (defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin or serum creatinine \\>265.2 μmol\u002FL \\[3.0 mg\u002FdL\\]);\n17. Women who are pregnant or lactating, or who have a positive pregnancy test prior to randomization;\n18. Life expectancy \\\u003C6 months (e.g., due to malignancy or severe cardiopulmonary disease);\n19. Participation in another interventional clinical trial that may affect outcome assessment;\n20. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation or poses significant risk (e.g., inability to understand or comply with study procedures or follow-up due to psychiatric, cognitive, or emotional disorders).",{"count":55,"type":20},234,[23,24],"Acute ischemic stroke (AIS) is a leading cause of mortality and long-term disability worldwide. Among these, stroke caused by large vessel occlusion (LVO) are associated with particularly poor outcomes. Multiple randomized controlled trials have demonstrated that endovascular thrombectomy (EVT) significantly improves clinical outcomes in patients with acute LVO and is recommended as the standard of care by current guidelines. Posterior circulation strokes account for approximately 20% of all ischemic strokes and are generally associated with worse prognosis than anterior circulation strokes, especially in patients with basilar artery occlusion, who have a markedly increased risk of death or severe disability. Despite EVT treatment, more than three-quarters of these patients remain dead or functionally dependent at 90 days, indicating substantial room for improvement.\n\nSuccessful recanalization and restoration of effective cerebral perfusion are critical for achieving favorable outcomes. However, although recanalization rates exceed 80% with current thrombectomy techniques, fewer than 40 of patients achieve good functional outcomes at 90 days, suggesting a high incidence of futile recanalization. The underlying mechanisms may include no-reflow, reperfusion injury, and microcirculatory dysfunction, all of which are closely associated with post-recanalization neuroinflammation.\n\nMinocycline is a second-generation tetracycline with pleiotropic neuroprotective properties, including inhibition of microglial activation, reduction of inflammatory mediators, suppression of matrix metalloproteinases, attenuation of oxidative stress, and preservation of blood-brain barrier integrity. Preclinical and clinical studies suggest that minocycline may improve neurological outcomes in patients with AIS.\n\nThis study is a multicenter, prospective, double-blind, randomized controlled trial designed to evaluate the safety and efficacy of adjunctive minocycline in patients with acute posterior circulation arterial occlusion who achieve successful recanalization after EVT. The trial will assess whether early administration of minocycline improves functional outcomes and reduces the incidence of futile recanalization.",[27,29,31,59,60],"Posterior Circulation","Arterial Occlusion",[27,29,31,62],"Posterior Circulation Arterial Occlusion","2026-05-19",{"date":35,"type":38},{"date":63,"type":38},{"date":42,"type":20},{"name":44,"class":45},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":92,"locationsCount":46},"100616226","phase-2-intra-arterial-recombinant-human-tenecteplase-tissue-type-plasminogen-activator-rhtnk-tpa-thrombolysis-for-acute-medium-vessel-occlusion-100616226","NCT07302854","Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion","Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion -- A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial","MeVO-TNK Ⅱ","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Pre-stroke mRS score 0-1\n3. Baseline NIHSS ≥4 or symptoms deemed clearly disabling by treating physician (e.g., hemianopia, aphasia, or motor dysfunction)\n4. Isolated medium distal vessel occlusion (i.e., an occlusion of the co-\u002Fnon-dominant M2, the M3\u002FM4 segment of the MCA, the A1\u002FA2\u002FA3 segment of the ACA or the P1\u002FP2\u002FP3 segment of the PCA) confirmed by CT angiography (CTA) or MR angiography (MRA)\n5. Acute ischemic stroke within 24 hours of symptom onset, including wake-up stroke or unwitnessed stroke; The onset time of symptoms was defined as the last time of normal performance.\n6. Acute ischemic stroke within 6-24 hours of onset, meeting at least one of the following imaging criteria:\n\n   1. Evidence of a hypoperfusion-ischemic core mismatch on CT or MRI perfusion, defined as an ischemic core volume \\\u003C50mL, hypoperfused tissue volume to ischemic core volume ratio ≥1.2, and mismatch volume ≥10 mL\n   2. Evidence of a diffusion-hyperintensity mismatch, defined as absence of hyperintensity on fluidattenuated inversion recovery (FLAIR) imaging within ≥ 90% of the area of the diffusion weighted imaging (DWI) lesion)\n7. The participant or legally authorized representative is capable of providing informed consent\n\nExclusion Criteria:\n\n1. Evidence of intracranial hemorrhage\n2. Any active bleeding (gastrointestinal, urinary, hemorrhagic retinopathy, etc.) or parenchymal organ surgery or biopsy within 30 days before stroke; Severe head trauma or stroke within the past 3 months\n3. Persistent and uncontrolled hypertension, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg\n4. Inherited or acquired hemorrhagic tendancy; deficiency of anticoagulant factors; or on oral anticoagulant with an INR\\> 1.7\n5. Blood glucose \\\u003C2.8 mmol\u002FL (50 mg\u002Fdl) or \\> 22.2mmol\u002FL (400 mg\u002Fdl), platelets count \\\u003C100\\*109\u002FL, or hemoglobin \\\u003C70g\u002FL\n6. Severe hepatic insufficiency, chronic hemodialysis and severe renal insufficiency (or recent blood tests suggesting a glomerular filtration rate \\\u003C30 ml\u002Fmin or blood creatinine\\> 200 mmol\u002FL (2.5 mg\u002Fdl)\n7. Women who are pregnant or breastfeeding\n8. Allergy to rhTNK-tPA or radiocontrast agent\n9. Participation in other clinical trials\n10. Expected survival time less than 6 months (e.g., due to malignancy, severe cardiopulmonary disease, etc.)\n11. Other conditions deemed by the investigator to make the patient unsuitable for participation or pose significant risks (e.g., inability to understand and\u002For comply with study procedures and\u002For follow-up due to mental illness, cognitive or emotional disorders)",{"count":77,"type":20},382,[23,24],"Medium vessel occlusion (MeVO) accounts for 20-45% of acute ischemic stroke (AIS). Although patients with MeVO often present with relatively low NIHSS scores, up to one-third remain functionally dependent at follow-up despite receiving standard medical therapy, including intravenous thrombolysis. Recent randomized trials (DISTAL, ESCAPE-MeVO, DISCOUNT) have not demonstrated clinical benefit of endovascular treatment (EVT) for MeVO and have suggested higher risks of symptomatic intracranial hemorrhage and mortality, underscoring the need for safer and more targeted reperfusion strategies.\n\nIntra-arterial thrombolysis (IAT) enables localized, high-concentration thrombolytic delivery with minimal mechanical manipulation, which may be advantageous for medium and distal vessels. Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA), a genetically engineered third-generation thrombolytic agent, has shown favorable pharmacologic properties and clinical safety in AIS, including in intra-arterial use following EVT. However, prospective evidence supporting its direct therapeutic role in MeVO-related AIS remains lacking.\n\nThis multicenter, prospective, open-label randomized controlled trial with blinded endpoint assessment is designed to evaluate the efficacy and safety of intra-arterial rhTNK-tPA thrombolysis in improving functional outcome in MeVO within 24 hours of symptom onset.",[27,81],"Medium Vessel Occlusion",[27,83,84,85],"medium vessel occlusion","Intra-arterial thrombolysis","Tenecteplase","2026-01-19",{"date":88,"type":38},"2026-01-21",{"date":90,"type":38},"2025-12-30",{"date":42,"type":20},{"name":44,"class":45},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100611429","phase-2-bovis-calculus-stativus-treat-acute-cerebral-ischemic-stroke-with-impaired-consciousness-100611429","NCT07240467","Bovis Calculus Stativus Treat Acute Cerebral Ischemic Stroke With Impaired Consciousness","Safety and Efficacy of Bovis Calculus Stativus in the Treatment of Acute Cerebral Ischemic Stroke With Impaired Consciousness- A Multicenter, Prospective, Double-blind, Randomized Trial","ASCENT-BC","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Clinically diagnosed with ischemic cerebral infarction;\n* GCS score: 3-12;\n* Time from symptom onset to randomization ≤ 24 hours, including wake-up stroke or stroke without a witness; the time of symptom onset is defined as the \"last known well time\";\n* Pre-stroke mRS score of 0-1;\n* Head CT excludes intracranial hemorrhage or other non-ischemic pathologies;\n* The participant or legally authorized representative is capable of providing informed consent.\n\nExclusion Criteria:\n\n* Use of in BCS within 24 hours before treatment;\n* Known pregnancy or breastfeeding, or positive pregnancy test before randomization;\n* Allergy to BCS;\n* Impaired consciousness caused by other diseases, such as metabolic disorders (e.g., ketoacidosis), trauma, infectious diseases (e.g., pneumonia), neoplastic diseases (e.g., glioma), or toxic conditions (e.g., organophosphate poisoning);\n* Requiring or undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency (glomerular filtration rate \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL);\n* Expected survival time less than 6 months (e.g., due to malignancy, severe cardiopulmonary disease, etc.);\n* Participation in other interventional clinical studies that may affect outcome assessment;\n* Other conditions deemed by the investigator to make the patient unsuitable for participation or pose significant risks (e.g., inability to understand and\u002For comply with study procedures and\u002For follow-up due to mental illness, cognitive or emotional disorders).",{"count":102,"type":20},220,[23,24],"Acute ischemic stroke (AIS) is a severe and life-threatening condition, with 35% of AIS patients experiencing impaired consciousness upon admission within 24 hours of onset. Previous studies indicated that patients with impaired consciousness at the onset of stroke have a higher incidence of stroke-related complications, particularly cerebral edema and pneumonia, as well as higher in-hospital and three-month mortality rates. The etiology of impaired consciousness in AIS is complex: ischemic damage to reticular activating system of the brainstem can directly lead to cell necrosis and result in impaired consciousness. Furthermore, secondary pathological changes following AIS, such as excitatory amino acid toxicity, oxidative stress, free radical production, and cascading inflammatory responses, can indirectly worsen impaired consciousness. Therefore, impaired consciousness at the onset of AIS is the result of cellular damage under multiple pathophysiological mechanisms. Developing neuroprotective drugs with multiple targets is key to effectively improving adverse outcomes related to impaired consciousness in AIS. However, there is currently a lack of treatment specifically aimed at improving impaired consciousness at the onset of AIS.\n\nCultivated Bovine Bezoar (Bovis Calculus Stativus, BCS) combines the advantages of pharmacological similarity to natural bovine by adding components such as deoxycholic acid, cholic acid, and composite calcium bilirubin to fresh bovine bile. It is rich in various trace elements and amino acids and is a compound medication that can exert neuroprotective effects through multiple pathways and targets. In traditional Chinese medicine, it has long been used to treat various consciousness disorder-related diseases, including stroke. The various components of in vitro cultivated bezoar are also widely used in clinical research for various neurological diseases.The above evidence fully demonstrates that BCS is an optimal treatment for impaired consciousness in stroke.\n\nThe goal of this clinical trial is to learn if Bovis Calculus Stativus works to treat acute cerebral ischemic stroke with impaired consciousness. It will also learn about the safety of Bovis Calculus Stativus. The main questions it aims to answer are:\n\n1. Does Bovis Calculus Stativus treat and alleviate consciousness disorders in patients with acute cerebral infarction accompanied by impaired consciousness ？\n2. What medical problems do participants have when taking Bovis Calculus Stativus?\n\nResearchers will compare Bovis Calculus Stativus to a placebo (a look-alike substance that contains no drug) to see if Bovis Calculus Stativus works to treat acute cerebral ischemic stroke with impaired consciousness.\n\nParticipants will:\n\n1. receive treatment with Bovis Calculus Stativus (or placebo) for 5 days.\n2. Take an in-person or telephone follow-up within 90 days after the acute stroke.",[106,107],"Acute Ischemic Stroke AIS","Impaired Consciousness",[109,110,111],"acute ischemic stroke","impaired consciousness","Bovis Calculus Stativus","NOT_YET_RECRUITING","2025-12-10",{"date":115,"type":38},"2025-12-18",{"date":117,"type":20},"2025-12-15",{"date":119,"type":20},"2028-12-15",{"name":44,"class":45},""]